This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Join us for a CRA-moderated panel discussion with leaders in Digital Therapeutics. Learn how key players are reacting to emerging challenges, and which...
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...
